Læknaneminn - 01.04.1997, Side 136

Peter Duesberg and David Rasnick
syndrome: a possible role of nitrites in Kaposi’s sarcoma. J SexTrans
Dis 1985; 12: 203-208.
218. Rappoport J. AIDS INC. Human Energy Press, San Bruno, CA,
1988.
219. Fettner AG, Check WA. The Truth about AIDS: Evolution of an
Epidemic. Holt, Rinehart and Wilson, New York, 1985.
220. Oppenheimer GM. Causes, cases, and cohorts: The role of epi-
demiology in the historical construction of AIDS, in AIDS: The
Making of a Chronic Disease, E. Fee and D. M. Fox (eds.)
University of California Press, Berkeley, 1992; 49-83.
221. Lang S. HIV and AIDS: Have we been misled? Questions of sci-
entific and journalistic resposibility, in AIDS: virus or drug-
induced?, P. Duesberg (eds.) Kluwer, Academic publishers,
Dordrecht, The N etherlands/Boston/London, 1996; 241-270.
222. CraddockM. A critical appraisal of the Vancouver men’s study; does
it refute the drugs/AIDS hypothesis?, in AIDS: virus or drug-
induced, P. H. Duesberg (eds.) Kluwer Academic Publishers,
Dordrecht, Netherland, 1996; 105-110.
223. Duesberg P. Aetiology of AIDS. Lancet 1993; 341: 1544.
224. Centers for Disease Control. Update: Outbreak of Ebola viral hem-
orrhagic fever - Zaire, 1995. Morb Mort Weekly Reports 1995; 44:
399.
225. Duesberg P. “The Duesberg-Phenomenon”: Duesberg and Other
Voices (letter). Science 1995; 267: 313.
226. Ward JW, Bush TJ, Perkins HA, Lieb LE, Allen JR, Goldfinger D,
Samson SM, Pepkowitz SH, Fernando LP, Holland PV, Kleinman
SH, Grindon AJ, Garner JL, Rutherford GW, Holmberg SD. The
natural history of transfusion-associated infection with human
immunodeficiency virus. N Engl J Med 1989; 321: 947-952.
227. Centers for Disease Control and Prevention. U.S. HIV and AIDS
cases reported through June 1994, Mid-Year Edition. HIV/AIDS
Surveillance Report 1994; 6: 1-27.
228. Centers for Disease Control. Update: acquired immunodeficiency
syndrome—United States. Morbidity and Mortality Weekly
Reports 1985; 34: 245-248.
229. Haverkos HW, Drotman DP. Measuring inhalant nitrite exposure
in gay men: implications for elucidating the etiology of AIDS-relat-
ed Kaposi’s sarcoma. Genetica 1995; 95: 157-164.
230. National Institute on Drug Abuse. Annual Emergency Room Data
1990. 1990;
231. Mok JQ, De Rossi A, Ades AE, Giaquinto C, Grosch-Woerner I,
Peckham CS. Infants born to mothers seropositive for human
immunodeficiency virus. Lancet 1987; i: 1164-1168.
232. European Collaborative Study. Children born to women with HIV-
1 infection: natural history and risk of transmission. Lancet 1991;
337: 253-260.
233. Rodriguez EM, Mofenson LM, Chang B-H, Rich KC, Fowler MG,
Smeriglio V, Landesman S, Fox HE, Diaz C, Green K, Hanson IC,
for the Women and Infants Transmission Study. Association of
maternal drug use during pregnancy with maternal HIV culture pos-
itivity and perinatal HIV transmission. AIDS 1996; 10: 273-282.
234. Irwin DH, Kaplan LD. Pulmonary manifestations of acquired
immunodeficiency syndrome-associated malignancies. Seminars in
Respiratory Infections 1993; 8: 139-148.
235. Gill PS, Akli B, Coletti P, Rarick M, Louriero C, Bernstein-Singer
M, Krailo M, M. LA. Pulmonary Kaposis sarcoma: clinical find-
ings and results of therapy. Am J Med 1989; 87: 57-61.
236. Meduri GU, Stover DE, Lee M, Myskowski PL, Caravelli JF, Zama
MB. Pulmonary Kaposi’s sarcoma in the acquired immune defi-
ciency syndrome: clinical, radiographic, and pathologic manifesta-
tions. AmJMedl986; 81: 11-18.
237. Sloand E, Kumar PN, Pierce PF. Chemotherapy for patients with
pulmonary Kaposi’s sarcoma: benefit of filgrastim (G-CSF) in sup-
porting dose administration. Southern Medical Journal 1993; 86:
1219-1224.
238. Garay SM, Belenko M, Fazzini E, Schinella R. Pulmonary manifes-
tations of Kaposi’s sarcoma. Chest 1987; 91: 39-43.
239. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut.
Archiv fur Dermatologie und Syphilis 1872; 2: 265-273.
240. Drotman DP, Haverkos H. What Causes Kaposi’s Sarcoma?
Inquiring Epidemiologists Want to Know. Epidemiology 1992; 3:
191-193.
241. Toufexis A. Innocent victims. Time 1991; 137: 56-60,
242. Schuster CR. Foreword, in Cocaine: Pharmacology, Effects and
Treatment of Abuse, J. Grabowski (eds.) National Institute on Drug
Abuse, Washington, DC, 1984; VII-VIII.
243. Savona S, Nardi MA, Lenette ET, Karpatkin S. Thrombocytopenic
purpura in narcotics addicts. Ann Intern Med 1985; 102: 737-741.
244. Donahoe RM, Bueso-Ramos C, Donahoe F, Madden JJ, Falek A,
Nicholson JKA, Bokos P. Mechanistic implications of the findings
that opiates and other drugs of abuse moderate T-celI surface recep-
tors and antigenic markers. Annals of the New York Academy of
Sciences 1987; 496: 711-721.
245. Espinoza P, Bouchard I, Buffet C, Thiers V, Pillot J, Etienne JP.
High prevalence of infection by hepatitis B virus and HIV in incar-
cerated French drug addicts. Gastroenterologie Clinique et
Biologique 1987; 11: 288-292.
246. Weber R, Ledergerber W, Opravil M, Siegenthaler W, Liithy R.
Progression of HIV infection in misusers of injected drugs who stop
injecting or follow a programme of maintenance treatment with
methadone. BrMedJ 1990; 301: 1362-1365.
247. Associated Press. Study Finds Ex-Smokers Still Risk Lung Cancer.
San Francisco Chronicle (San Francisco) 1995: A5, May 23.
248. Cohen J. New clues found to how some people live with HIV.
Science 1995; 270: 917-918.
249. Learmont J, Tindall B, Evans L, Cunningham A, Cunningham P,
Wells J, Penny R, Kaldor J, Cooper DA. Long-term symptomless
HIV-1 infection in recipients of blood products from a single donor.
Lancet 1992; 340: 863-867.
250. McCarthy M. Attenuated HIV-1 strains share gene deletyions.
Lancet 1995; 346: 1357.
251. Cao Y, Quin L, Zhang L, Safrit J, Ho DD. Virologic and
Immunologic Characterization of Long-Term Survivors of Human
Immunodeficiency Virus Type 1 Infection. N Engl J Med 1995;
332: 201-208.
252. Munoz A. Disease progression 15 percent of HlV-infected men will
be long-term survivors. AIDS Weekly, (News Report) 1995; May,
15 & 29: 5-6 & 3-4.
253. Gavzer B. Love has Helped Keep me Alive. Parade Magazine 1995;
4-6, April 16.
254. Wells J. We have to question the so-called ‘facts’. Capital Gay 1993:
14-15, August 20th.
255. Root-Bernstein RS. Five myths about AIDS that have misdirected
research and treatment. Genetica 1995; 95: 111-132.
256. Callen M. Surviving AIDS. HarperPerennial, New York, 1990.
257. Gorman C. Time 1993; 49, 22 March.
258. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ,
Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et
al. Studies in subjects with long-term nonprogressive human
immunodeficiency virus infection. N Engl J Med 1995; 332: 209-
216.
259. Munoz A, Kirby AJ, He YD, Margolick JB, Visscher BR, Rinaldo
CR, Kaslow RA, Phair JP. Long-term survivors with HIV-1 infec-
tion: incubation period and longitudinal patterns of CD4+ lympho-
cytes. Journal of Acquired Immune Deficiency Syndromes and
Human Retrovirology 1995; 8: 496-505.
260. Hoover DR, Rinaldo C, He Y, Phair J, Fahey J, Graham NM. Long-
term survival without clinical AIDS after CD4+ cell counts fall
below 200 x 10 (6)/l. AIDS 1995; 9: 145-152.
261. Hogervorst E, Jurriaans S, De Wolf F, Van Wijk A, Wiersma A, Valk
M, Roos M, Van Gemen B, Coutinho R, Miedema F, et al.
Predictors for non- and slow progression in human immunodefi-
ciency virus (HIV) type 1 infection: low viral RNA copy numbers in
serum and maintenance of high HIV-1 p24-specific but not V3-spe-
cific antibody levels. Journal of Infectious Diseases 1995; 171: 811-
821.
262. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M,
Miralles GD, Fauci AS. Neutralizing and infection-enhancing anti-
body responses to human immunodeficiency virus type 1 in long-
term nonprogressors. Journal of Infectious Diseases 1996; 173: 60-
67.
263. HarrerT, Harrer E, Kalams SA, ElbeikT, Staprans SI, Feinberg MB,
Cao Y, Ho DD, Yilma T, Caliendo AM, et al. Strong cytotoxic T
cell and weak neutralizing antibody responses in a subset of persons
LÆKNANEMINN -|34 1. tbl. 1997, 50. árg.